63:@0.890196:0.957873:0.907378:0.957873:0.907378:0.938882:0.890196:0.938882:0.008591:0.008591
3:@0.941813:0.310836:0.963291:0.310836:0.963291:0.263358:0.941813:0.263358:0.021478
PATIENT-DERIVED OVARIAN CANCER ORGANOIDS MIMIC CLINICAL RESPONSE AND:@0.411230:0.057372:0.882353:0.057372:0.882353:0.040253:0.411230:0.040253:0.007583:0.007097:0.006387:0.003511:0.006985:0.008759:0.005640:0.005155:0.008423:0.006985:0.008423:0.003511:0.007620:0.006985:0.008423:0.002988:0.008328:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.008442:0.008311:0.008292:0.007919:0.008759:0.008442:0.003511:0.008423:0.007807:0.002988:0.011112:0.003511:0.011112:0.003511:0.008255:0.002988:0.008255:0.006481:0.003511:0.008759:0.003511:0.008177:0.007919:0.006294:0.002988:0.008423:0.006871:0.007807:0.008050:0.008442:0.008759:0.007807:0.006985:0.002801:0.007919:0.008759:0.008423
EXHIBIT HETEROGENEOUS INTER- AND INTRAPATIENT DRUG RESPONSES:@0.468171:0.073247:0.882352:0.073247:0.882352:0.056128:0.468171:0.056128:0.006985:0.007527:0.008685:0.003511:0.008236:0.003511:0.006201:0.002988:0.008685:0.006985:0.006387:0.006985:0.008309:0.008442:0.008404:0.006985:0.008759:0.006985:0.008442:0.008367:0.007807:0.002988:0.003511:0.008759:0.006387:0.006985:0.008423:0.005155:0.002800:0.007919:0.008759:0.008423:0.002988:0.003511:0.008759:0.006387:0.008423:0.007919:0.007581:0.007097:0.006387:0.003511:0.006985:0.008759:0.006201:0.002988:0.008423:0.008367:0.008367:0.008404:0.002988:0.008423:0.006873:0.007807:0.008050:0.008442:0.008759:0.007807:0.006871:0.007807
system is the possibility to study genetic and phenotypic tumor heterogeneity .:@0.147059:0.121273:0.815544:0.121273:0.815544:0.100900:0.147059:0.100900:0.007761:0.009724:0.007510:0.006209:0.009039:0.017645:0.004109:0.005615:0.007670:0.004109:0.006620:0.011299:0.009039:0.004109:0.011502:0.010957:0.007533:0.007601:0.005547:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.004109:0.006209:0.011048:0.004109:0.007510:0.006163:0.011345:0.011322:0.009724:0.004109:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004109:0.009085:0.011596:0.011391:0.004109:0.011162:0.011299:0.009039:0.011596:0.010820:0.006437:0.009724:0.011071:0.005547:0.008994:0.004109:0.006163:0.011413:0.017485:0.010843:0.007807:0.004109:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.018244:0.004497
125:@0.792803:0.113657:0.811048:0.113657:0.811048:0.101780:0.792803:0.101780:0.006082:0.006082:0.006082
In this study, we systematically assessed if :@0.147059:0.141852:0.496283:0.141852:0.496283:0.121479:0.147059:0.121479:0.006894:0.011756:0.003972:0.006620:0.011459:0.005615:0.007670:0.003972:0.007510:0.006163:0.011345:0.011322:0.007989:0.004497:0.003972:0.014518:0.009039:0.003972:0.007761:0.009724:0.007510:0.006211:0.009039:0.017577:0.008809:0.006437:0.005547:0.009108:0.009405:0.005387:0.005182:0.009724:0.003972:0.009291:0.007533:0.007875:0.009039:0.007531:0.007875:0.009108:0.011391:0.003972:0.005615:0.006209:0.004109
in vitro:@0.496188:0.142321:0.561199:0.142321:0.561199:0.120299:0.496188:0.120299:0.005935:0.012144:0.005068:0.010500:0.005912:0.006802:0.007921:0.010729
 drug response of OC PDOs correlates :@0.561192:0.141852:0.886425:0.141852:0.886425:0.121479:0.561192:0.121479:0.003972:0.011391:0.007964:0.011413:0.009861:0.003972:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.003972:0.010843:0.006209:0.003972:0.016778:0.014678:0.003972:0.011664:0.016504:0.016253:0.007670:0.003972:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008809:0.006211:0.009039:0.007670:0.004109
to patients’ clinical response to chemotherapeutics. We studied inter- and intrapatient :@0.147059:0.162431:0.886370:0.162431:0.886370:0.142058:0.147059:0.142058:0.006209:0.011048:0.006118:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.006277:0.004291:0.006118:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.006118:0.007442:0.009039:0.007510:0.011502:0.010843:0.011621:0.007873:0.009039:0.006118:0.006209:0.011048:0.006118:0.008768:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008809:0.011505:0.009131:0.011071:0.006437:0.005547:0.008994:0.007670:0.004497:0.006118:0.018649:0.009039:0.006118:0.007510:0.006163:0.011347:0.011391:0.005545:0.009108:0.011391:0.006118:0.005615:0.011391:0.006209:0.009039:0.007236:0.007533:0.006118:0.009085:0.011596:0.011391:0.006118:0.005615:0.011391:0.006437:0.007898:0.008811:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004109
drug response heterogeneity to a wide range of chemotherapeutics as well as targeted :@0.147059:0.183009:0.886512:0.183009:0.886512:0.162636:0.147059:0.162636:0.011391:0.007967:0.011413:0.009861:0.006277:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.006277:0.011299:0.009131:0.006209:0.009039:0.007442:0.011048:0.009656:0.009039:0.011596:0.009039:0.005273:0.006437:0.009724:0.006277:0.006211:0.011048:0.006277:0.009291:0.006277:0.014723:0.005547:0.011322:0.009039:0.006277:0.007898:0.009085:0.011459:0.009656:0.009039:0.006277:0.010843:0.006209:0.006277:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011505:0.009131:0.011071:0.006437:0.005547:0.008994:0.007670:0.006277:0.009291:0.007670:0.006277:0.014518:0.008948:0.005387:0.005250:0.006277:0.009291:0.007670:0.006277:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004109
drugs, and linked differential drug response to genetic variation.:@0.147059:0.203588:0.684305:0.203588:0.684305:0.183215:0.147059:0.183215:0.011391:0.007967:0.011413:0.009724:0.007670:0.004497:0.004109:0.009085:0.011596:0.011391:0.004109:0.005250:0.005615:0.011868:0.010272:0.009108:0.011391:0.004109:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.004109:0.011391:0.007964:0.011413:0.009861:0.004109:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004109:0.006209:0.011048:0.004109:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.008994:0.004109:0.009838:0.009085:0.007807:0.005798:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497
Results:@0.147059:0.251844:0.227127:0.251844:0.227127:0.223733:0.147059:0.223733:0.013103:0.010895:0.012144:0.013015:0.008541:0.010226:0.012144
PDOs can be (rapidly) established from different OC subtypes:@0.147059:0.273966:0.694120:0.273966:0.694120:0.250806:0.147059:0.250806:0.010733:0.011231:0.011256:0.010409:0.003984:0.010907:0.010558:0.011679:0.003984:0.010982:0.009363:0.003984:0.006873:0.011231:0.010558:0.010733:0.004856:0.011231:0.006945:0.010309:0.006873:0.003984:0.009211:0.010309:0.007520:0.010558:0.010982:0.008691:0.004856:0.010409:0.011579:0.009363:0.011231:0.003984:0.008840:0.011081:0.011256:0.014817:0.003984:0.011231:0.004856:0.008840:0.008840:0.009363:0.011231:0.009363:0.011679:0.008365:0.003984:0.011256:0.011007:0.003984:0.010409:0.011156:0.010880:0.008616:0.010309:0.010733:0.009214:0.010409
In total, we included 36 PDOs (of which 29 were established previously ), derived from :@0.147059:0.323532:0.886460:0.323532:0.886460:0.303160:0.147059:0.303160:0.006894:0.011756:0.003812:0.006209:0.010820:0.006551:0.009405:0.004976:0.004497:0.003812:0.014518:0.009039:0.003812:0.005615:0.011596:0.008765:0.004908:0.011345:0.011322:0.009108:0.011391:0.003812:0.010432:0.010432:0.003812:0.011664:0.016504:0.016253:0.007670:0.003812:0.006939:0.010843:0.006209:0.003812:0.014792:0.011459:0.005545:0.008765:0.011459:0.003812:0.010432:0.010432:0.003812:0.014520:0.009039:0.007442:0.009039:0.003812:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011299:0.009108:0.011391:0.003812:0.011071:0.007442:0.009336:0.009838:0.005545:0.010822:0.011413:0.007556:0.005182:0.009724:0.018257:0.006939:0.004497:0.003812:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.003812:0.006414:0.007442:0.010843:0.017645:0.004109
278:@0.738856:0.315916:0.757101:0.315916:0.757101:0.304039:0.738856:0.304039:0.006082:0.006082:0.006082
23 patients with different histological subtypes of OC who underwent primary or inter-:@0.147059:0.344111:0.882353:0.344111:0.882353:0.323738:0.147059:0.323738:0.010432:0.010432:0.004383:0.011365:0.008813:0.006437:0.005545:0.009039:0.011391:0.006437:0.007670:0.004383:0.014723:0.005273:0.006620:0.011459:0.004383:0.011391:0.005615:0.005969:0.005784:0.009039:0.007444:0.009039:0.011391:0.006437:0.004383:0.011459:0.005615:0.007508:0.006209:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.004383:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.007670:0.004383:0.010843:0.006209:0.004383:0.016778:0.014678:0.004383:0.014792:0.011299:0.011048:0.004383:0.011413:0.011596:0.011322:0.009039:0.008398:0.014518:0.009039:0.011393:0.006437:0.004383:0.011071:0.007807:0.005615:0.017577:0.009085:0.008400:0.009724:0.004383:0.010843:0.007807:0.004383:0.005615:0.011391:0.006209:0.009039:0.007284:0.007533
val debulking surgery or ascites drainage (:@0.147059:0.364690:0.495804:0.364690:0.495804:0.344317:0.147059:0.344317:0.009838:0.009405:0.005250:0.003629:0.011322:0.008900:0.010797:0.011550:0.005387:0.010706:0.005615:0.011459:0.009861:0.003629:0.007510:0.011413:0.007624:0.009656:0.009039:0.008400:0.009724:0.003629:0.010843:0.007807:0.003629:0.009291:0.007875:0.008994:0.005271:0.006211:0.009039:0.007670:0.003629:0.011391:0.007898:0.009085:0.005615:0.011687:0.009199:0.009656:0.009039:0.003629:0.006939
Table S1:@0.495799:0.364690:0.568868:0.364690:0.568868:0.343557:0.495799:0.343557:0.011413:0.009679:0.011528:0.005935:0.009473:0.003538:0.010592:0.010911
). PDO sample names are informative :@0.568877:0.364690:0.886466:0.364690:0.886466:0.344317:0.568877:0.344317:0.006939:0.004497:0.003629:0.011662:0.016504:0.016412:0.003629:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.003629:0.011690:0.009085:0.017485:0.009039:0.007670:0.003629:0.009085:0.007442:0.009039:0.003629:0.005615:0.011756:0.006026:0.010843:0.007807:0.017577:0.008811:0.006437:0.005547:0.009633:0.009039:0.004109
of histological subtype as well as patient (first number) and tumor location (second num-:@0.147059:0.385269:0.882353:0.385269:0.882353:0.364896:0.147059:0.364896:0.010843:0.006209:0.003310:0.011459:0.005615:0.007510:0.006209:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.003310:0.007510:0.011345:0.010797:0.006437:0.009724:0.011505:0.009039:0.003310:0.009291:0.007670:0.003310:0.014518:0.008948:0.005387:0.005250:0.003310:0.009291:0.007670:0.003310:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.003310:0.006939:0.005684:0.005684:0.007624:0.007510:0.006437:0.003310:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.006939:0.003310:0.009085:0.011596:0.011391:0.003310:0.006163:0.011413:0.017488:0.010843:0.007807:0.003310:0.005182:0.011274:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.003310:0.006939:0.007875:0.009108:0.008994:0.010843:0.011596:0.011391:0.003310:0.011391:0.011413:0.017734:0.007533
ber). We have previously demonstrated that PDOs are largely similar to the carcinoma :@0.147059:0.405847:0.886352:0.405847:0.886352:0.385474:0.147059:0.385474:0.011254:0.009039:0.007807:0.006939:0.004497:0.005341:0.018649:0.009039:0.005341:0.011391:0.008925:0.009633:0.009039:0.005341:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.005341:0.011322:0.009039:0.017485:0.010843:0.011619:0.007510:0.006437:0.007898:0.008811:0.006209:0.009108:0.011391:0.005341:0.006620:0.011391:0.008811:0.006437:0.005341:0.011664:0.016504:0.016253:0.007670:0.005341:0.009085:0.007442:0.009039:0.005341:0.005430:0.009085:0.007626:0.009656:0.008948:0.005182:0.009724:0.005341:0.007601:0.005615:0.017645:0.005752:0.005433:0.009085:0.007807:0.005341:0.006211:0.011048:0.005341:0.006620:0.011299:0.009039:0.005341:0.009108:0.009085:0.007442:0.008994:0.005615:0.011596:0.010843:0.017577:0.009291:0.004109
fields within their matching tumor, based on histopathological assessment . The major-:@0.147059:0.426426:0.882353:0.426426:0.882353:0.406053:0.147059:0.406053:0.005684:0.005615:0.008948:0.005182:0.011391:0.007670:0.003607:0.014723:0.005271:0.006620:0.011459:0.005615:0.011756:0.003607:0.006620:0.011299:0.009039:0.005615:0.007807:0.003607:0.017577:0.008811:0.006209:0.008765:0.011459:0.005615:0.011459:0.009861:0.003607:0.006163:0.011413:0.017485:0.010843:0.006255:0.004497:0.003607:0.011114:0.009291:0.007875:0.009108:0.011391:0.003607:0.010843:0.011756:0.003607:0.011459:0.005615:0.007510:0.006209:0.010820:0.011368:0.008811:0.006620:0.011299:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009402:0.005250:0.003607:0.009291:0.007533:0.007875:0.009039:0.007533:0.007601:0.017485:0.009039:0.011391:0.006437:0.018208:0.004497:0.003607:0.011470:0.011311:0.009039:0.003607:0.017577:0.008811:0.005339:0.010843:0.007228:0.007533
278:@0.763247:0.418810:0.781492:0.418810:0.781492:0.406933:0.763247:0.406933:0.006082:0.006082:0.006082
ity of PDOs in our biobank were thoroughly characterized by whole-genome sequencing :@0.147059:0.447005:0.886510:0.447005:0.886510:0.426632:0.147059:0.426632:0.005273:0.006437:0.009724:0.003310:0.010843:0.006209:0.003310:0.011664:0.016504:0.016253:0.007670:0.003310:0.005615:0.011756:0.003310:0.010822:0.011413:0.007807:0.003310:0.010820:0.005547:0.010957:0.011117:0.009085:0.011870:0.010523:0.003310:0.014518:0.009039:0.007442:0.009039:0.003310:0.006620:0.011299:0.010843:0.007442:0.010820:0.011413:0.009930:0.011573:0.005182:0.009724:0.003310:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009108:0.011391:0.003310:0.010843:0.009724:0.003310:0.014792:0.011299:0.010934:0.005182:0.009039:0.007533:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.003310:0.007873:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004109
and histopathological examination and biobanked prior to drug testing, to establish a re-:@0.147059:0.467583:0.882353:0.467583:0.882353:0.447210:0.147059:0.447210:0.009085:0.011596:0.011391:0.003607:0.011459:0.005615:0.007510:0.006209:0.010820:0.011368:0.008811:0.006620:0.011299:0.010934:0.005182:0.011048:0.009861:0.005547:0.009106:0.009405:0.005250:0.003607:0.009108:0.010089:0.009085:0.017645:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.003607:0.009085:0.011596:0.011391:0.003607:0.010820:0.005547:0.010957:0.011114:0.009087:0.011870:0.010272:0.009106:0.011391:0.003607:0.011071:0.007807:0.005547:0.010843:0.007807:0.003607:0.006209:0.011048:0.003607:0.011391:0.007967:0.011413:0.009861:0.003607:0.006209:0.009039:0.007510:0.006437:0.005615:0.011459:0.009679:0.004497:0.003607:0.006209:0.011048:0.003607:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.003607:0.009291:0.003607:0.007442:0.009110:0.007533
liable platform. This resulted in a considerable length of time from PDO establishment to :@0.147059:0.488162:0.886368:0.488162:0.886368:0.467789:0.147059:0.467789:0.005250:0.005798:0.009108:0.010911:0.005182:0.009039:0.003333:0.011162:0.005433:0.008811:0.006437:0.006026:0.010843:0.007807:0.017645:0.004497:0.003333:0.011470:0.011470:0.005615:0.007670:0.003333:0.007442:0.009039:0.007510:0.011550:0.004905:0.006211:0.009106:0.011391:0.003333:0.005615:0.011756:0.003333:0.009291:0.003333:0.008994:0.010840:0.011621:0.007601:0.005547:0.011322:0.009039:0.007898:0.009106:0.010911:0.005184:0.009039:0.003333:0.005182:0.009039:0.011459:0.009861:0.006620:0.011459:0.003333:0.010843:0.006209:0.003333:0.006437:0.005615:0.017485:0.009039:0.003333:0.006414:0.007442:0.010843:0.017645:0.003333:0.011664:0.016501:0.016412:0.003333:0.009039:0.007512:0.006549:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.017485:0.009039:0.011391:0.006437:0.003333:0.006209:0.011048:0.004109
drug screening. However, in order to incorporate PDO-based drug response prediction :@0.147059:0.508741:0.886482:0.508741:0.886482:0.488368:0.147059:0.488368:0.011391:0.007967:0.011413:0.009861:0.004383:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009679:0.004497:0.004383:0.016207:0.010866:0.014518:0.009336:0.009633:0.009039:0.006255:0.004497:0.004383:0.005615:0.011756:0.004383:0.010843:0.007442:0.011322:0.009039:0.007807:0.004383:0.006209:0.011048:0.004383:0.005615:0.011596:0.008994:0.010840:0.007967:0.011505:0.010843:0.007898:0.008811:0.006209:0.009039:0.004383:0.011664:0.016504:0.016412:0.007533:0.011117:0.009291:0.007875:0.009108:0.011391:0.004383:0.011391:0.007964:0.011413:0.009861:0.004383:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004383:0.011071:0.007442:0.009108:0.011391:0.005547:0.009108:0.006437:0.005545:0.010845:0.011756:0.004109
in clinical care, PDO establishment and screening must be executed within a short time :@0.147059:0.529320:0.886457:0.529320:0.886457:0.508947:0.147059:0.508947:0.005615:0.011756:0.004451:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004451:0.009106:0.009087:0.007442:0.008743:0.004497:0.004451:0.011664:0.016504:0.016412:0.004451:0.009039:0.007510:0.006549:0.009108:0.010911:0.005250:0.005615:0.007556:0.011459:0.017485:0.009039:0.011391:0.006437:0.004451:0.009087:0.011596:0.011391:0.004451:0.007875:0.008994:0.007442:0.009106:0.009039:0.011756:0.005615:0.011459:0.009861:0.004451:0.017280:0.011413:0.007510:0.006437:0.004451:0.011251:0.009039:0.004451:0.009106:0.009884:0.009108:0.009108:0.011071:0.006209:0.009108:0.011391:0.004451:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004451:0.009291:0.004451:0.007556:0.011299:0.010843:0.007967:0.006437:0.004451:0.006437:0.005615:0.017485:0.009039:0.004109
span. As a pilot experiment, we successfully established and rapidly screened organoids :@0.147059:0.549898:0.886391:0.549898:0.886391:0.529525:0.147059:0.529525:0.007510:0.011368:0.009085:0.011756:0.004497:0.004657:0.014586:0.007670:0.004657:0.009291:0.004657:0.011071:0.005752:0.005182:0.010820:0.006437:0.004657:0.009108:0.010089:0.011502:0.009039:0.007807:0.005615:0.017485:0.009039:0.011391:0.006437:0.004497:0.004657:0.014518:0.009039:0.004657:0.007510:0.011345:0.008994:0.008994:0.009039:0.007533:0.007601:0.006366:0.011553:0.005385:0.005182:0.009724:0.004657:0.009039:0.007510:0.006551:0.009108:0.010911:0.005250:0.005615:0.007556:0.011299:0.009108:0.011391:0.004657:0.009085:0.011596:0.011391:0.004657:0.007898:0.008811:0.011071:0.005545:0.011528:0.005182:0.009724:0.004657:0.007875:0.008994:0.007442:0.009108:0.009039:0.011596:0.009108:0.011391:0.004657:0.010845:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004109
from a patient with recurrent disease (HG-26; :@0.147059:0.570477:0.537965:0.570477:0.537965:0.550104:0.147059:0.550104:0.006414:0.007442:0.010843:0.017645:0.004428:0.009291:0.004428:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004428:0.014723:0.005273:0.006620:0.011459:0.004428:0.007444:0.009108:0.009106:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.004428:0.011391:0.005615:0.007875:0.009291:0.009291:0.007875:0.009039:0.004428:0.006939:0.016410:0.015682:0.007533:0.010432:0.010432:0.004497:0.004109
Figure S1A-C:@0.538252:0.570477:0.658604:0.570477:0.658604:0.549344:0.538252:0.549344:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004326:0.010592:0.010911:0.014356:0.007213:0.014769
). Within 20 days of tumor :@0.658605:0.570477:0.886484:0.570477:0.886484:0.550104:0.658605:0.550104:0.006939:0.004497:0.004428:0.019951:0.005273:0.006620:0.011459:0.005615:0.011756:0.004428:0.010432:0.010432:0.004428:0.011573:0.008925:0.009724:0.007670:0.004428:0.010843:0.006209:0.004428:0.006163:0.011413:0.017488:0.010840:0.007807:0.004109
collection the response to six therapies became available.:@0.147059:0.591056:0.621052:0.591056:0.621052:0.570683:0.147059:0.570683:0.008994:0.010934:0.005387:0.005182:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.004109:0.006620:0.011299:0.009039:0.004109:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.004109:0.006209:0.011048:0.004109:0.007601:0.005615:0.010089:0.004109:0.006620:0.011299:0.009039:0.007898:0.008811:0.011071:0.005547:0.009039:0.007670:0.004109:0.011254:0.009106:0.009108:0.009085:0.017488:0.009039:0.004109:0.008923:0.009838:0.009087:0.005750:0.005433:0.009108:0.010911:0.005182:0.008743:0.004497
PDOs retained genomic features of the original tumor lesion:@0.147059:0.648498:0.687745:0.648498:0.687745:0.625338:0.147059:0.625338:0.010733:0.011231:0.011256:0.010409:0.003984:0.011231:0.009363:0.007520:0.010558:0.004856:0.011679:0.009363:0.011231:0.003984:0.011206:0.009363:0.011679:0.011256:0.014817:0.004856:0.011007:0.003984:0.008840:0.009363:0.009458:0.008616:0.011156:0.011231:0.009214:0.010409:0.003984:0.011256:0.008840:0.003984:0.008616:0.011579:0.009363:0.003984:0.011256:0.011231:0.004856:0.011206:0.004856:0.011679:0.010558:0.008439:0.003984:0.008616:0.011156:0.014817:0.011256:0.011231:0.003984:0.008691:0.009211:0.010409:0.004856:0.011256:0.011679
We characterized 36 organoids, 30 matching tumors and 31 germline samples by :@0.147059:0.698065:0.886375:0.698065:0.886375:0.677692:0.147059:0.677692:0.018649:0.009039:0.009610:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.009106:0.011391:0.009610:0.010432:0.010432:0.009610:0.010843:0.007624:0.009861:0.009085:0.011598:0.010840:0.005549:0.011391:0.007670:0.004497:0.009610:0.010432:0.010432:0.009610:0.017577:0.008811:0.006209:0.008768:0.011459:0.005615:0.011459:0.009861:0.009610:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.009610:0.009085:0.011596:0.011391:0.009610:0.010432:0.010432:0.009610:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.009610:0.007941:0.009087:0.017280:0.011162:0.005182:0.009039:0.007670:0.009610:0.010843:0.009724:0.004109
whole-genome sequencing to an average coverage of 32X. Passage numbers at which :@0.147059:0.718644:0.886487:0.718644:0.886487:0.698271:0.147059:0.698271:0.014792:0.011299:0.010934:0.005182:0.009039:0.007533:0.009656:0.009039:0.011596:0.010843:0.017485:0.009039:0.006711:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.006711:0.006209:0.011048:0.006711:0.009085:0.011756:0.006711:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.006711:0.008994:0.010866:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.006711:0.010843:0.006209:0.006711:0.010432:0.010432:0.014107:0.004497:0.006711:0.011413:0.009291:0.007533:0.007944:0.009199:0.009656:0.009039:0.006711:0.011391:0.011413:0.017394:0.011254:0.009039:0.007624:0.007670:0.006711:0.008811:0.006437:0.006711:0.014792:0.011459:0.005547:0.008765:0.011459:0.004109
PDOs were sequenced are provided in :@0.147059:0.739222:0.469441:0.739222:0.469441:0.718849:0.147059:0.718849:0.011664:0.016504:0.016253:0.007670:0.003492:0.014520:0.009039:0.007442:0.009039:0.003492:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.003492:0.009085:0.007442:0.009039:0.003492:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009106:0.011391:0.003492:0.005615:0.011756:0.004109
Table S1:@0.468807:0.739222:0.541750:0.739222:0.541750:0.718089:0.468807:0.718089:0.011413:0.009679:0.011528:0.005935:0.009473:0.003413:0.010592:0.010911
. First, we compared the genomic profiles :@0.541749:0.739222:0.886477:0.739222:0.886477:0.718849:0.541749:0.718849:0.004497:0.003492:0.011388:0.005615:0.007624:0.007510:0.006437:0.004497:0.003492:0.014518:0.009039:0.003492:0.008994:0.010843:0.017280:0.011368:0.009085:0.007442:0.009108:0.011391:0.003492:0.006620:0.011299:0.009039:0.003492:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.003492:0.011071:0.007442:0.010843:0.005684:0.005821:0.005182:0.009039:0.007670:0.004109
of PDOs and the tumors they were derived from. An average of 8,290 and 10,358 SNVs :@0.147059:0.759801:0.886530:0.759801:0.886530:0.739428:0.147059:0.739428:0.010843:0.006209:0.004497:0.011664:0.016504:0.016253:0.007670:0.004497:0.009085:0.011596:0.011391:0.004497:0.006620:0.011299:0.009039:0.004497:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.004497:0.006617:0.011302:0.009334:0.009724:0.004497:0.014518:0.009039:0.007442:0.009039:0.004497:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.004497:0.006414:0.007442:0.010843:0.017645:0.004497:0.004497:0.014929:0.011756:0.004497:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.004497:0.010843:0.006209:0.004497:0.010432:0.004497:0.010432:0.010432:0.010432:0.004497:0.009085:0.011596:0.011391:0.004497:0.010432:0.010432:0.004497:0.010432:0.010432:0.010432:0.004497:0.009770:0.016230:0.015089:0.007670:0.004109
were identified in the parental tumor specimen and their matched PDO, respectively. On :@0.147059:0.780380:0.886510:0.780380:0.886510:0.760007:0.147059:0.760007:0.014518:0.009039:0.007442:0.009039:0.003492:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.003492:0.005615:0.011756:0.003492:0.006620:0.011299:0.009039:0.003492:0.011365:0.009087:0.007442:0.009039:0.011391:0.006551:0.009402:0.005250:0.003492:0.006163:0.011413:0.017485:0.010843:0.007807:0.003492:0.007510:0.011505:0.009108:0.008994:0.005615:0.017485:0.009039:0.011756:0.003492:0.009085:0.011596:0.011391:0.003492:0.006620:0.011302:0.009039:0.005615:0.007807:0.003492:0.017577:0.008811:0.006209:0.008765:0.011299:0.009108:0.011391:0.003492:0.011664:0.016504:0.015385:0.004497:0.003492:0.007442:0.009039:0.007510:0.011505:0.009108:0.009108:0.006437:0.005545:0.009635:0.008948:0.005182:0.007989:0.004497:0.003492:0.016298:0.011756:0.004109
average 67% of variants were shared between the tumor and PDO, 6% of the SNVs were :@0.147059:0.800958:0.886352:0.800958:0.886352:0.780585:0.147059:0.780585:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.004360:0.010432:0.010432:0.015043:0.004360:0.010845:0.006209:0.004360:0.009838:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.007670:0.004360:0.014518:0.009039:0.007442:0.009039:0.004360:0.007556:0.011391:0.009085:0.007444:0.009106:0.011391:0.004360:0.011251:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.004360:0.006620:0.011299:0.009039:0.004360:0.006163:0.011413:0.017485:0.010843:0.007807:0.004360:0.009085:0.011598:0.011391:0.004360:0.011664:0.016504:0.015385:0.004497:0.004360:0.010432:0.015043:0.004360:0.010843:0.006209:0.004360:0.006620:0.011299:0.009039:0.004360:0.009770:0.016230:0.015089:0.007670:0.004360:0.014518:0.009039:0.007442:0.009039:0.004109
unique to the tumor, and 27% to the PDO (:@0.147059:0.821537:0.515828:0.821537:0.515828:0.801164:0.147059:0.801164:0.011413:0.011756:0.005547:0.010706:0.011345:0.009039:0.004931:0.006209:0.011048:0.004931:0.006620:0.011299:0.009039:0.004931:0.006163:0.011413:0.017485:0.010843:0.006255:0.004497:0.004931:0.009087:0.011596:0.011391:0.004931:0.010432:0.010432:0.015043:0.004931:0.006209:0.011048:0.004931:0.006620:0.011299:0.009039:0.004931:0.011664:0.016504:0.016412:0.004931:0.006939
Figure S2A:@0.515748:0.821537:0.615342:0.821537:0.615342:0.800404:0.515748:0.800404:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004816:0.010592:0.010911:0.015089
). Assessment of CNAs demon-:@0.615337:0.821537:0.882353:0.821537:0.882353:0.801164:0.615337:0.801164:0.006939:0.004497:0.004931:0.014586:0.007533:0.007875:0.009039:0.007533:0.007601:0.017485:0.009039:0.011391:0.006437:0.004931:0.010843:0.006209:0.004931:0.014678:0.015408:0.014586:0.007670:0.004931:0.011322:0.009039:0.017485:0.010843:0.011721:0.007533
strated comparable copy-number states in the majority of pairs (:@0.147059:0.842116:0.695331:0.842116:0.695331:0.821743:0.147059:0.821743:0.007510:0.006437:0.007898:0.008811:0.006209:0.009108:0.011391:0.005273:0.008994:0.010843:0.017280:0.011368:0.009085:0.007898:0.009108:0.010911:0.005182:0.009039:0.005273:0.008994:0.010820:0.011092:0.009724:0.007533:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.005273:0.007510:0.006551:0.008811:0.006209:0.009039:0.007670:0.005273:0.005615:0.011756:0.005273:0.006620:0.011299:0.009039:0.005273:0.017577:0.008811:0.005341:0.010843:0.007807:0.005271:0.006437:0.009724:0.005273:0.010843:0.006209:0.005273:0.011368:0.009085:0.005615:0.007624:0.007670:0.005273:0.006939
Figure S2B-C:@0.695318:0.842116:0.815912:0.842116:0.815912:0.820983:0.695318:0.820983:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.005159:0.010592:0.010911:0.013765:0.007213:0.014769
). HGS-:@0.815906:0.842116:0.882355:0.842116:0.882355:0.821743:0.815906:0.821743:0.006939:0.004497:0.005273:0.016412:0.015682:0.010112:0.007533
3.1, LGS-2.2 and MC-2.1 presented with a much higher number of SNVs than their :@0.147059:0.862695:0.886375:0.862695:0.886375:0.842322:0.147059:0.842322:0.010432:0.004497:0.010432:0.004497:0.006848:0.011528:0.015682:0.010112:0.007533:0.010432:0.004497:0.010432:0.006848:0.009085:0.011596:0.011391:0.006848:0.019197:0.014678:0.007533:0.010432:0.004497:0.010432:0.006848:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006209:0.009108:0.011391:0.006848:0.014723:0.005273:0.006620:0.011459:0.006848:0.009291:0.006848:0.017280:0.011347:0.008765:0.011459:0.006848:0.011459:0.005615:0.009930:0.011299:0.009039:0.007807:0.006848:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.006848:0.010843:0.006209:0.006848:0.009770:0.016230:0.015089:0.007670:0.006848:0.006620:0.011391:0.009085:0.011756:0.006848:0.006620:0.011299:0.009039:0.005615:0.007807:0.004109
matched tumor specimen and considerable CNA dissimilarities within PDO-tumor :@0.147059:0.883273:0.886418:0.883273:0.886418:0.862900:0.147059:0.862900:0.017577:0.008811:0.006209:0.008765:0.011299:0.009108:0.011391:0.008058:0.006163:0.011413:0.017485:0.010843:0.007807:0.008058:0.007510:0.011505:0.009108:0.008994:0.005615:0.017485:0.009039:0.011756:0.008058:0.009085:0.011598:0.011391:0.008058:0.008994:0.010843:0.011619:0.007601:0.005547:0.011322:0.009039:0.007898:0.009108:0.010911:0.005182:0.009039:0.008058:0.014678:0.015408:0.014929:0.008058:0.011391:0.005615:0.007533:0.007601:0.005615:0.017645:0.005750:0.005433:0.009085:0.007807:0.005273:0.006437:0.005547:0.009039:0.007670:0.008058:0.014723:0.005273:0.006617:0.011459:0.005615:0.011756:0.008058:0.011664:0.016504:0.016412:0.007533:0.006163:0.011413:0.017488:0.010843:0.007807:0.004109
pairs. These exceptions are likely due to a high degree of normal cell contamination in :@0.147059:0.903852:0.886370:0.903852:0.886370:0.883479:0.147059:0.883479:0.011368:0.009085:0.005615:0.007624:0.007670:0.004497:0.005478:0.011470:0.011311:0.009039:0.007875:0.009039:0.005478:0.009108:0.009884:0.008994:0.009131:0.011048:0.006437:0.005547:0.010843:0.011619:0.007670:0.005478:0.009085:0.007442:0.009039:0.005478:0.005250:0.005752:0.010272:0.008948:0.005182:0.009724:0.005478:0.011048:0.011345:0.009039:0.005478:0.006209:0.011048:0.005478:0.009291:0.005478:0.011459:0.005615:0.009927:0.011459:0.005478:0.011322:0.009039:0.009861:0.007442:0.009108:0.009039:0.005478:0.010843:0.006209:0.005478:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.005478:0.008994:0.008948:0.005387:0.005250:0.005478:0.008994:0.010843:0.011391:0.006551:0.009085:0.017645:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.005478:0.005615:0.011756:0.004109